Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, the Netherlands.
Department of Medical Oncology, University Medical Centre Utrecht, the Netherlands.
J Geriatr Oncol. 2020 Apr;11(3):482-487. doi: 10.1016/j.jgo.2019.05.016. Epub 2019 May 31.
OBJECTIVES: No tools accurately discriminate between older patients who are fit and those who are frail to tolerate systemic palliative treatment. This study evaluates whether domains of geriatric assessment (GA) are associated with increased risk of chemotherapy intolerance in patients who were considered fit to start palliative chemotherapy after clinical evaluation by their treating clinician. MATERIALS AND METHODS: This prospective multicenter study included patients ≥70 years who started first line palliative systemic treatment. Before treatment initiation, patients completed GA including Activities of Daily Life (ADL), Instrumental Activities of Daily Life (IADL), Mini-Mental State Examination (MMSE), Mini Nutritional Assessment (MNA), Geriatric Depression Scale (GDS-15) and the Timed Up and Go Test (TUGT). Primary endpoint was treatment modification, defined as inability to complete the first three sessions of systemic treatment as planned. Secondary endpoint was treatment related toxicity ≥ grade 3 (CTCAE Version 4). The association between GA and endpoints were assessed using univariable and multivariable logistic regression analysis. RESULTS: Ninety-nine patients with median age of 77 (+/- 8) years underwent GA. 48% of the patients required treatment modification and grade 3 toxicity occurred in 53% of patients. One or more geriatric impairments were present in 71% of patients and 32% of patients were frail in two or more domains. Only TUGT was associated with treatment modifications (OR 2.9 [95% CI 1.3-6.5]) and grade 3 toxicities (OR 2.8 [95% CI 1.2-6.3]). CONCLUSION: Frailty was common in older patients who were considered fit to receive palliative chemotherapy. Treatment modification was necessary in half of the patients. Only TUGT was significantly associated with treatment modifications and grade 3 chemotherapy toxicities.
目的:没有工具能准确区分适合接受系统姑息治疗的老年患者和衰弱患者。本研究评估了在临床医生评估认为适合开始姑息化疗的患者中,老年综合评估(GA)的各个领域是否与化疗不耐受风险增加相关。
材料和方法:这项前瞻性多中心研究纳入了≥70 岁开始一线姑息性全身治疗的患者。在治疗开始前,患者完成了 GA,包括日常生活活动(ADL)、工具性日常生活活动(IADL)、简易精神状态检查(MMSE)、微型营养评估(MNA)、老年抑郁量表(GDS-15)和计时起立行走测试(TUGT)。主要终点是治疗调整,定义为无法按计划完成前三个疗程的全身治疗。次要终点是治疗相关毒性≥3 级(CTCAE 第 4 版)。使用单变量和多变量逻辑回归分析评估 GA 与终点之间的关系。
结果:99 名中位年龄为 77(+/-8)岁的患者进行了 GA。48%的患者需要治疗调整,53%的患者发生 3 级毒性。71%的患者存在 1 项或多项老年障碍,32%的患者在 2 个或更多领域虚弱。只有 TUGT 与治疗调整(OR 2.9 [95%CI 1.3-6.5])和 3 级毒性(OR 2.8 [95%CI 1.2-6.3])相关。
结论:在被认为适合接受姑息性化疗的老年患者中,衰弱很常见。一半的患者需要治疗调整。只有 TUGT 与治疗调整和 3 级化疗毒性显著相关。
J Geriatr Oncol. 2020-4
Support Care Cancer. 2013-11-28
Aging Clin Exp Res. 2023-6
J Clin Oncol. 2013-9-23
J Cancer Res Clin Oncol. 2010-9-4
Cancers (Basel). 2023-12-9